Latest First Analysis news

First Analysis acted as the exclusive financial advisor to Kazmira for its $50 million strategic investment by Perrigo Company (PRGO). In collaboration with Perrigo, the investment will be applied to scale up Kazmira’s facilities and laboratories, proactively engage with regulatory authorities, further develop Kazmira’s product portfolio, extend Kazmira’s reach into retail mass markets, and enhance Kazmira’s strong management and technical teams.

First Analysis, a leading venture capital investor, has made a new investment in Fortress Information Security, an information security and cyber risk mitigation company that has redefined traditional risk management. Fortress combines automation, continuous monitoring, vulnerability scanning and other powerful technology with human assets to deliver risk management solutions for critical infrastructure clients such as electric utilities.

First Analysis acted as the exclusive financial advisor to sticky.io (formerly LimeLight CRM) for its capital financing led by Flexpoint Ford. The First Analysis team worked closely with sticky.io to understand the industry and create a unit-based economic model while positioning the company optimally in the marketplace.

As First Analysis approaches its 40th year of using integrative research to uncover and leverage the best opportunities in emerging high-growth segments in technology and healthcare, it is enhancing its research model and increasing its commitment to publishing research on cutting-edge trends in technology and healthcare.

First Analysis, a leading venture capital investor, has made a new investment in VIDA Diagnostics Inc. (VIDA). VIDA provides the new standard of pulmonary care by using AI-powered CT imaging software and services to aid early detection, evaluation, and treatment planning for patients with or at risk of lung diseases. First Analysis led an $11 million initial close of the Series C round to accelerate the commercialization of VIDA’s LungPrint® solution suite.

First Analysis, a leading venture capital investor, has made a new minority investment in 4G Clinical. 4G Clinical is a global leader in randomization and trial supply management (RTSM) for the life sciences industry. First Analysis participated in the investment along with existing investors.

First Analysis Vice President Joseph Munda’s latest white paper explores the dynamic and rapidly evolving array of digital technology solutions related to drug commercialization. Munda highlights numerous promising opportunities in this burgeoning emerging sector. His work builds on his broad involvement in medical and pharmaceutical technology as well as his 2018 white paper, “eClinical Solutions: Streamlining the introduction of new drugs and medical technology.”

Chicago-based First Analysis Securities Corporation announced Andrew Walsh has joined the firm as a Managing Director. This move expands First Analysis’s investment banking practice and its commitment to advising premier companies in the firm’s healthcare sector.

First Analysis portfolio company Checkpoint Surgical, a leader in hand-held, intraoperative neurostimulation technology for nerve protection and repair, announced it has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for the Checkpoint brief electrostimulation therapy (BEST) system.